Myocardial Damage in COVID-19

• Conditions: COVID-19; Cardiovascular Diseases

• Registration Number: NCT04312464
• Lead Sponsor: Wuhan Union Hospital, China

Brief Summary

This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.

Detailed Description

The epidemic of the COVID-19 has expanded from Wuhan through out China, and is being exported to a growing number of countries. Recently, investigators have revealed that acute myocardial injury is existed in 7.2% patients with COVID-19, and this proportion in patients admitted to the ICU (22.2%) is higher than patients not treated in the ICU (2.0%). Thus, cardiac troponin I (cTNI), the biomarker of cardiac injury, might be a clinical predictor of COVID-19 patient outcomes. This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients.

Study Timeline

• Study Start: 2020-01-01
• Status Verified: 2020-03
• Study First Submitted: 2020-03-04
• Study First Submitted QC: 2020-03-13
• Last Update Submitted: 2020-03-13
• Primary Completion: 2020-03-15
• Study Completion: 2020-03-18
• Study First Posted: 2020-03-18
• Last Update Posted: 2020-03-18

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• (1) Age ≥18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3) Lung involvement confirmed with chest imaging.

Exclusion Criteria

• No cTnI test on admission

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The myocardial injury incidence	75 days	The myocardial injury incidence of COVID-19 patients
The risk factors analysis for the death	75 days	The risk factors analysis for the death of COVID-19 patients

Secondary Outcome Measures

Name	Time	Method
Cardiovascular comorbidity	75 days	The clinical characteristics and prognosis analysis in different cardiovascular comorbidity of COVID-19 patients
Analysis of causes of death	75 days	Analysis of causes of death in COVID-19 patients
Clinical characteristics	75 days	The clinical characteristics description of COVID-19 patients
Clinical course	75 days	The clinical course description of COVID-19 patients

Trial Locations

Locations (1)

Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China